Summary Results from Country Radio Seminar 2013
We are pleased to offer you a summary of the results of the Cleveland Heart Lab IT testing (Figure below) performed at the Country Radio Seminar in 2013. We are excited at the broad based participation and hope you all find it of some interest. In all 531 attendees participated.
As we did during our brief presentation we will divide our findings into patients who have classical risk based on a high LDL (>130 mg/dL), those who have evidence of atherosclerosis or hardening of the arteries based on a hsCRP >2.0, and those who have evidence of active arterial plaque (or vulnerable plaque) based on an MPO > 480 or a PLAC > 200. As seen in the figure below, 23% of attendees have risk based on their lipid profile. Focusing on the patients who had normal cholesterol levels, 25% have evidence of atheroma based on hsCRP and 11% have evidence of vulnerable plaque formation based on MPO and PLAC.
While these are interesting and medically valuable findings they do not tell the whole story of the CRS population, nor the insights gained through IT. As seen in the figure below, ~45% of attendees had no cardiovascular risk factors based on lipid panel or inflammatory markers (CONGRATULATIONS !), and for ~13% of attendees an abnormal lipid panel was the only risk factor they had.
Importantly, ~25% of the attendees had evidence of atherosclerosis based on a hsCRP > 2.0 but their lipid panel was normal !! Furthermore, 7% of the attendees had evidence of vulnerable plaque yet their lipid panel was normal !! Thus we identified ~32% of the attendees who have real risk for cardiovascular disease that would not be recognized based on classic lipid measurement. Furthermore we can further stratify the population by looking at combinations of the different test results. Based on this analysis the number and percent of patients identified with increasing risk are shown in the figure above.
There were several other measures performed that are beyond simple explanation in this general summary of results did not add much. We would be happy to answer questions about your specific results.
In summary, we had a diverse group of participants. We hope you found this of interest and you or your physician should feel free to contact us with any questions about the findings, but we need to keep treatment decisions between you and your physician.
It was great fun meeting you all and we look forward to doing it again.
Marc S. Penn, MD, PhD, FACC
Co-Founder and CMO, Cleveland Heart Lab
Director of Research, Summa Cardiovascular Institute, Summa Health System, Akron, OH